Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: A multicenter longitudinal study
| Autor: | Laiza M Steimbach, Helena Hl Borba, Roberto Pontarolo, Claudia Ivantes, Astrid Wiens, Maria La Pedroso, Fernando Fernandez-Llimos, Fernanda S. Tonin |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Longitudinal study Therapeutics and Clinical Risk Management rapid virological response protease inhibitors 02 engineering and technology multicenter Telaprevir 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Boceprevir Internal medicine medicine boceprevir Pharmacology (medical) telaprevir Oncology & Carcinogenesis General Pharmacology Toxicology and Pharmaceutics Original Research Chemical Health and Safety business.industry General Medicine Hepatitis C Odds ratio 021001 nanoscience & nanotechnology medicine.disease chemistry Cohort 030211 gastroenterology & hepatology hepatitis C 0210 nano-technology business Safety Research Viral load medicine.drug Cohort study |
| Zdroj: | Therapeutics and Clinical Risk Management |
| Popis: | Helena HL Borba,1 Astrid Wiens,1 Laiza M Steimbach,1 Fernanda S Tonin,1 Maria LA Pedroso,2 Cláudia AP Ivantes,3 Fernando Fernandez-Llimos,4 Roberto Pontarolo1 1Pharmaceutical Sciences Postgraduate Research Program, Department of Pharmacy, 2Gastroenterology Service, Hospital de Clínicas, Federal University of Paraná, 3Guidance and Counseling Center, Curitiba City Hall, Curitiba, Paraná, Brazil; 4Department of Social Pharmacy, Faculty of Pharmacy, Research Institute for Medicines, University of Lisboa, Lisbon, Portugal Background: Chronic hepatitis C is a major public health issue, but there is a gap in the literature regarding the effectiveness and safety of direct-acting antiviral agents in the Brazilian population. The main aim of this study was to describe the effectiveness of boceprevir and telaprevir in patients treated at public health care institutions in Brazil.Materials and methods: A prospective longitudinal and multicenter study was conducted in five centers in the State of Paraná between September 2014 and June 2016. Data regarding effectiveness and safety were collected from medical records of patients treated with boceprevir or telaprevir. The effectiveness outcome comprised the rapid virological response (RVR). Multivariate analysis was performed to verify the influence of independent variables (ie, age, gender, baseline viral load) on RVR achievement.Results: Data were collected from 117 patients with chronic hepatitis C virus (HCV) genotype 1 infection. Fifteen patients received treatment with boceprevir and 102 received telaprevir. The mean age was 51.6years, 64.1% were male, 44.4% were infected with HCV subtype 1a, 62.4% had a high baseline viral load (≥800,000IU/mL) and 33% were cirrhotic. Furthermore, 79.5% of patients achieved RVR (26.7% in the boceprevir group and 87.3% in the telaprevir group). Multivariate analysis demonstrated that the type of protease inhibitor (boceprevir or telaprevir) and the baseline viral load had an influence on the RVR rate (odds ratio [OR] =0.011; 95% confidence interval [CI]: 0.001–0.119; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|